SAB Biotherapeutics Inc logo

SAB Biotherapeutics Inc(SABS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$2.81
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SABS

11/20/2026: SABS (1-star) is currently NOT-A-BUY. Pass it for now.

SAB Biotherapeutics is a clinical-stage biotechnology company that utilizes a proprietary transchromosomic platform to develop fully human polyclonal antibody therapies for autoimmune diseases and infectious conditions. Its primary investment appeal centers on its lead clinical candidate, SAB-142, which targets Type 1 Diabetes with a potentially disease-modifying mechanism. However, the company faces notable risks, including a lack of commercial product revenue, historical operating losses, and ongoing cash burn that necessitates capital raises. Suited primarily for risk-tolerant growth investors, market participants should closely monitor upcoming clinical trial data readouts, regulatory updates, and cash management execution.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company offers high-growth potential tied to clinical pipeline milestones, but lacks consistent commercial revenue growth.
Momentum investorStrong fit while signal remains positiveThe stock can experience sharp price movements and high trading volume around clinical data releases and public offerings.
Value investorWeak fitAs a pre-revenue clinical biotech with ongoing cash burn, traditional valuation metrics like P/E ratios are inapplicable.
Dividend investorWeak fitThe company pays no dividends and retains all capital to fund drug development programs.
Low-risk investorWeak fitHigh clinical, regulatory, and financial volatility make this stock unsuitable for conservative or risk-averse investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighSmall-cap clinical-stage biotech stocks frequently experience sharp price swings driven by clinical updates and market conditions.
Valuation riskHighValuation relies heavily on speculative future pipeline success rather than current earnings or tangible revenues.
Competition risk (biopharmaceutical pipeline competition)Medium / highThe company faces intense competition from well-capitalized peers developing alternative therapies for diabetes and immune disorders.
Business qualityMediumWhile the DiversitAb platform is scientifically unique, the commercial viability of the platform remains unproven.
Dividend incomeLow / noneNo dividend distributions are paid to shareholders.
Execution riskHighSuccess depends entirely on successfully executing clinical trials, securing regulatory approvals, and commercializing drug candidates.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 253.15M USD
Price to earnings Ratio -
1Y Target Price 11.64
Price to earnings Ratio -
1Y Target Price 11.64
Volume (30-day avg) 717.0K shares
Beta 0.75
52 Weeks Range 2.44 - 5.15
Updated Date 11/21/2026
52 Weeks Range 2.44 - 5.15
Updated Date 11/21/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.35

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Biotechnology

BUY participation
43.2%
Active BUY / eligible
19 / 44
30-Day BUY Count Change
+12

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -41.84%
Avg. Invested days 22
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SABS receives a 3-star rating, supported by strong analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
SABS has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+138.9%) is partially offset by soft cash generation (FCF margin 0.0%), negative revenue growth (-100.0%), soft profitability (net margin 0.0%).

Financial Health Rating

★★★★★
SABS's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is SABS's strongest growth driver at +138.9% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (-100.0%, negative) and free-cash-flow growth (-32.0%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 84.7% and approximately 65.0% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 3.15% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

Caligan Partners LP 8.74%
Vivo Capital, LLC 8.01%
Perceptive Advisors LLC 7.27%
Adage Capital Partners Gp LLC 7.03%
RA Capital Management, LLC 4.83%

Unit Economics (Per $1K Revenue)

★★★★★
SABS generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
SABS has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Government Contracts & GrantsResearch funding and development awards from U.S. government agencies such as BARDA and the Department of Defense.Historically, most incoming funds have come via non-dilutive government research grants rather than commercial product sales.
Future Commercial TherapeuticsAnticipated future sales of proprietary human polyclonal antibody treatments like SAB-142 for Type 1 Diabetes and SAB-176 for influenza.The long-term investment case rests on successfully launching approved drugs into commercial healthcare markets.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 162.13M
Price to Sales(TTM) 2.96
Enterprise Value 162.13M
Price to Sales(TTM) 2.96
Enterprise Value to Revenue 1.21
Enterprise Value to EBITDA 64.16
Shares Outstanding 90.09M
Shares Floating 58.56M
Shares Outstanding 90.09M
Shares Floating 58.56M
Percent Insiders 3.15
Percent Institutions 84.73

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.